Lauren M Jansson1, Martha Velez2, Krystle McConnell2, Nancy Spencer3, Michelle Tuten4, Hendree E Jones5, Van L King6, Neeraj Gandotra6, Lorraine A Milio7, Kristin Voegtline2, Janet A DiPietro8. 1. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: ljansson@jhmi.edu. 2. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD. 3. Johns Hopkins Bayview Hospital, Department of Nursing, Baltimore, MD. 4. University of Maryland School of Social Work, Baltimore, MD. 5. Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD; University of North Carolina Chapel Hill, Department of Obstetrics and Gynecology. 6. Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD. 7. Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD. 8. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Abstract
BACKGROUND: Gestational opioid use/misuse is escalating in the United States; however, little is understood about the fetal effects of medications used to treat maternal opioid use disorders. OBJECTIVE: The purpose of this study was to determine the effect of maternal buprenorphine administration on longitudinal fetal neurobehavioral development. STUDY DESIGN: Forty-nine buprenorphine-maintained women who attended a substance use disorder treatment facility with generally uncomplicated pregnancies underwent fetal monitoring for 60 minutes at times of trough and peak maternal buprenorphine levels. Data were collected at 24, 28, 32, and 36 weeks gestation. Fetal neurobehavioral indicators (ie, heart rate, motor activity, and their integration [fetal movement-fetal heart rate coupling]) were collected via an actocardiograph, digitized and quantified. Longitudinal data analysis relied on hierarchic linear modeling. RESULTS: Fetal heart rate, heart rate variability, and heart rate accelerations were significantly reduced at peak vs trough maternal buprenorphine levels. Effects were significant either by or after 28 weeks gestation and tended to intensify with advancing gestation. Fetal motor activity and fetal movement-fetal heart rate coupling were depressed from peak to trough at 36 weeks gestation. Polysubstance exposure did not significantly affect fetal neurobehavioral parameters, with the exception that fetuses of heavier smokers moved significantly less than those of lighter smokers at 36 weeks gestation. By the end of gestation, higher maternal buprenorphine dose was related to depression of baseline fetal cardiac measures at trough. CONCLUSION: Maternal buprenorphine administration has acute suppressive effects on fetal heart rate and movement, and the magnitude of these effects increases as gestation progresses. Higher dose (≥13 mg) appears to exert greater depressive effects on measures of fetal heart rate and variability. These findings should be balanced against comparisons to gestational methadone effects, relatively good outcomes of buprenorphine-exposed infants, and recognition of the benefits of medication-assisted treatment for pregnant women with opioid use disorders in optimizing pregnancy outcomes.
BACKGROUND: Gestational opioid use/misuse is escalating in the United States; however, little is understood about the fetal effects of medications used to treat maternal opioid use disorders. OBJECTIVE: The purpose of this study was to determine the effect of maternal buprenorphine administration on longitudinal fetal neurobehavioral development. STUDY DESIGN: Forty-nine buprenorphine-maintained women who attended a substance use disorder treatment facility with generally uncomplicated pregnancies underwent fetal monitoring for 60 minutes at times of trough and peak maternal buprenorphine levels. Data were collected at 24, 28, 32, and 36 weeks gestation. Fetal neurobehavioral indicators (ie, heart rate, motor activity, and their integration [fetal movement-fetal heart rate coupling]) were collected via an actocardiograph, digitized and quantified. Longitudinal data analysis relied on hierarchic linear modeling. RESULTS: Fetal heart rate, heart rate variability, and heart rate accelerations were significantly reduced at peak vs trough maternal buprenorphine levels. Effects were significant either by or after 28 weeks gestation and tended to intensify with advancing gestation. Fetal motor activity and fetal movement-fetal heart rate coupling were depressed from peak to trough at 36 weeks gestation. Polysubstance exposure did not significantly affect fetal neurobehavioral parameters, with the exception that fetuses of heavier smokers moved significantly less than those of lighter smokers at 36 weeks gestation. By the end of gestation, higher maternal buprenorphine dose was related to depression of baseline fetal cardiac measures at trough. CONCLUSION: Maternal buprenorphine administration has acute suppressive effects on fetal heart rate and movement, and the magnitude of these effects increases as gestation progresses. Higher dose (≥13 mg) appears to exert greater depressive effects on measures of fetal heart rate and variability. These findings should be balanced against comparisons to gestational methadone effects, relatively good outcomes of buprenorphine-exposed infants, and recognition of the benefits of medication-assisted treatment for pregnant women with opioid use disorders in optimizing pregnancy outcomes.
Authors: Elizabeth E Krans; Debra Bogen; Gale Richardson; Seo Young Park; Shannon L Dunn; Nancy Day Journal: Subst Abus Date: 2016-02-25 Impact factor: 3.716
Authors: Hendrée E Jones; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Amelia M Arria; Kevin E O'Grady; Peter Selby; Peter R Martin; Gabriele Fischer Journal: N Engl J Med Date: 2010-12-09 Impact factor: 91.245
Authors: Stephen W Patrick; Robert E Schumacher; Brian D Benneyworth; Elizabeth E Krans; Jennifer M McAllister; Matthew M Davis Journal: JAMA Date: 2012-04-30 Impact factor: 56.272
Authors: Lauren M Jansson; Robin Choo; Martha L Velez; Cheryl Harrow; Jennifer R Schroeder; Diaa M Shakleya; Marilyn A Huestis Journal: Pediatrics Date: 2008-01 Impact factor: 7.124
Authors: D Andrew Tompkins; George E Bigelow; Joseph A Harrison; Rolley E Johnson; Paul J Fudala; Eric C Strain Journal: Drug Alcohol Depend Date: 2009-08-03 Impact factor: 4.492
Authors: Jean Y Ko; Stephen W Patrick; Van T Tong; Roshni Patel; Jennifer N Lind; Wanda D Barfield Journal: MMWR Morb Mortal Wkly Rep Date: 2016-08-12 Impact factor: 17.586
Authors: Elisabeth Conradt; Tess Flannery; Judy L Aschner; Robert D Annett; Lisa A Croen; Cristiane S Duarte; Alexander M Friedman; Constance Guille; Monique M Hedderson; Julie A Hofheimer; Miranda R Jones; Christine Ladd-Acosta; Monica McGrath; Angela Moreland; Jenae M Neiderhiser; Ruby H N Nguyen; Jonathan Posner; Judith L Ross; David A Savitz; Steven J Ondersma; Barry M Lester Journal: Pediatrics Date: 2019-09 Impact factor: 9.703
Authors: Rosalyn Singleton; Amanda Slaunwhite; Mary Herrick; Matthew Hirschfeld; Laura Brunner; Christine Hallas; Sarah Truit; Sally Hanson; Margaret Young; Evelyn Rider Journal: Int J Circumpolar Health Date: 2019-12 Impact factor: 1.228